PremiumCompany AnnouncementsCodeBreaK 100: Amgen’s KRAS Trial Update and What It Means for AMGN Investors1d agoAMGN
PremiumRatingsAnalyst Reiterates Buy on Gilead, Keeping Yeztugo‑Driven Outlook Intact with Unchanged $168 Price Target1d agoGILD
Analyst Reiterates Buy on Gilead, Keeping Yeztugo‑Driven Outlook Intact with Unchanged $168 Price Target